Stock screener

RAPP

Conviction 81HealthcareScan · Thu, Jun 25, 2026
RAPP$38.83-2.93%
ResistanceSupportVol 14Insider sell
63 bars
6
6
6
6
5
Vol MA14 342.79K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Rapport Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.rapportrx.com
Price38.83
Change-2.93%
Gap+0.80%
Rel volume1.04×
Avg volume315.05K
Avg $ vol11.76M
SMA 2037.49
SMA 5037.05
SMA 20030.30
Price vs 50+4.80%
Price vs 200+28.13%
MA stackbullish
50/200 cross
Supertrendup · 33.66
RSI (14)55
MACD hist0.20
MACD crossbull · 3d
Stoch %K / %D64 / 75
ADX (14)23
+DI / −DI27 / 14
RSI divergence
MACD divergence
ATR %+6.08%
ADR %5.94%
52w high40.00
52w low11.31
From 52w high-2.93%
Above 52w low+243.32%
New 52w highNo
SqueezeOn · 8d
Bollinger width15.86%
%B0.73
Donchian pos63.69%
Donchian high41.86
Donchian low33.51
AVWAP (52w high)29.91
vs AVWAP high+29.83%
AVWAP (52w low)28.60
vs AVWAP low+35.77%
OBV trendFlat
Chaikin MF (20)-0.07
Today vs 20d1.04×
Avg vol (14d)342.79K
Avg vol (20d)315.05K
Avg $ vol (20d)11.76M
Market cap1.86B
RS 3m (vs SPY)+29.34%
RS 6m (vs SPY)+21.92%
RS line new highNo
Trend template8/8
Technical rank76.7
1 week+5.32%
1 month-2.22%
3 months+34.45%
6 months+21.72%
1 year+213.65%
YTD+38.14%
P/E-16.66
P/B3.94
P/S
P/FCF-21.08
EPS-2.86
Div yield
ROE-23.64%
ROA-22.40%
Debt/Eq
Current27.08
EV/EBITDA-14.34
Gross margin
Net margin
Rev growth
EPS growth-42.37%
Price target55.25
Target upside42.29%
Analyst ratingBuy
Institutional113.52%
Ent. value1.78B
Revenue20M
Net income-19.86M
Gross profit
Free cash flow-88.09M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out47.83M
Employees84
ListedFri, Jun 7, 2024
Free float29.26M
Float %61.2%
Short interest2.46M
Days to cover8.6d
Short volume37.7%
Squeeze score42 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.88 · 2 est
Last EPS vs est−$0.42 vs −$0.56
Last surprise+25.0% beat
Setup gradeA
Conviction81 / 100
Pattern quality
Tech rank76.7 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance40.76
Support33.66
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RAPP

All disclosures →
No recent disclosed trades by Congress in RAPP. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RAPP · 8 buys · 1 sell

InsiderSideShares
HEALY JAMES
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
PEREZ ROBERT J
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
Young Wendy B.
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
Silva Paul M
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
MARAGANORE JOHN
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
PAUL STEVEN M
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
Sanchez Ramiro
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
Huber Reid M
Director · Stock Option (Right to Buy) · 2026-06-10
Grant15.2K
Third Rock Ventures VI, L.P.
10% owner · Common Stock · 2026-05-26
Other
Third Rock Ventures VI, L.P.
10% owner · Common Stock · 2026-05-26
Sell18.57K

SEC filings

EDGAR filings in RAPP · 1 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.